Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glioblastomas multiforme (GBM) are the most frequently occurring malignant brain cancers. Treatment for GBM consists of surgical resection and subsequent adjuvant radiation therapy and chemotherapy. Despite this, GBM patient survival is limited to 12-15 months, and researchers are continually trying to develop improved therapy options. Insulin-like growth factor 2 mRNA-binding protein 2 (Imp2) is known to be upregulated in many cancers and is known to regulate the signaling activity of insulin-like growth factor 2 (IGF2). However, relatively little is known about its role in malignant development of GBM. In this study, we first found Imp2 is upregulated in GBM tissues by using clinical samples and public database search. Studies with loss and gain of Imp2 expression in in vitro GBM cell culture system demonstrated the role of Imp2 in promoting GBM cell proliferation, migration, invasion and epithelial-to-mesenchymal transition (EMT). Additionally, our results show that Imp2 regulates the activity of IGF2, which further activates PI3K/Akt signaling, thereby to promote GBM malignancy. Inhibition of Imp2 was also found to sensitize GBM to temozolomide treatment. These observations add to the current knowledge of GBM biology, and may prove useful in development of more effective GBM therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry
Dai, N., Rapley, J., Angel, M., Yanik, M. F., Blower, M. D., & Avruch, J. (2011) · Genes & Development · doi:10.1101/gad.2042311 · Cited by 208 · cited 4×
“These data indicate that implicates Imp2 may activate IGF2/PI3K/Akt signaling axis in human GBMs. www.tandfonline.com 625Cancer Biology & Therapy Imp2 promotes cell proliferation via activating IGF2/PI3K/ Akt pathway PI3K/Akt pathway plays central role in GBM biology and inhibition of PI3K/Akt can lead to reduced GBM…”
BackgroundInfluential
Cited by
Xu, X., Yu, Y., Zong, K., Lv, P., & Gu, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1470-y · Cited by 203
Dai, N., Ji, F., Wright, J., Minichiello, L., Sadreyev, R., & Avruch, J. (2017) · eLife · doi:10.7554/elife.27155 · Cited by 103
“IMP2 is amplified and overexpressed in many cancers and recent reports (Li et al., 2015; Liu et al., 2015; Mu et al., 2015) have pointed to a tumorogenic role in individual cancer types, often with a poor prognosis (Barghash et al.”
BackgroundHuang, R.-S., Zheng, Y.-L., Li, C., Ding, C., Xu, C., & Zhao, J. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.03.005 · Cited by 73
Suo, M., Rommelfanger, M. K., Chen, Y., Amro, E. M., Han, B., Chen, Z., Szafranski, K., Chakkarappan, S. R., Boehm, B. O., MacLean, A. L., et al. (2022) · Blood · doi:10.1182/blood.2021012197 · Cited by 57
Self-citationXing, M., Li, P., Wang, X., Li, J., Shi, J., Qin, J., Zhang, X., Ma, Y., Francia, G., & Zhang, J.-Y. (2019) · Cancers · doi:10.3390/cancers12010007 · Cited by 39
Self-citation
Metadata
- Authors
- Mu, Q., Wang, L., Yu, F., Gao, H., Lei, T., Li, P., Liu, P., Zheng, X., Hu, X., Chen, Y., Jiang, Z., Sayari, A. J., Shen, J., & Huang, H.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-02-26
- Volume
- 16
- Issue
- 4
- Pages
- 623-633
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W1830662843
- Cited by
- 89
- References
- 4
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. https://app.cochat.ai/papers/10.1080/15384047.2015.1019185
- The paper
- Mu, Q., Wang, L., Yu, F., Gao, H., Lei, T., Li, P., Liu, P., Zheng, X., Hu, X., Chen, Y., Jiang, Z., Sayari, A. J., Shen, J., & Huang, H. (2015). Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cancer Biology & Therapy. https://doi.org/10.1080/15384047.2015.1019185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.